tirzepatide 11.25 mg Dosage Chart & Dosing Guide for Weight Loss In adults with obesity but

Ahead, well break down what typically changes after stopping tirzepatide and walk through practical ways to protect your results and stay steady long term, even without weekly injections

In the SURMOUNT-1 clinical trial the average weight loss after 72 weeks was 15% for the 5mg dose, 19.5% for the 10mg dose and 20.9% for the 15mg dose

This occurs because tirzepatide reduces appetite and improves insulin sensitivity through GLP-1 and GIP receptor activation, and these effects diminish once the medication leaves your system

Emotional and psychological considerations The medical facts only tell part of the story

For research subjects this means stronger appetite control with fewer GI side-effects per kilo lost, plus emerging data on cardiometabolic, liver and sleep-apnoea endpoints

SO FAR SO GOOD